0A0D Stock Chart & Stats
CHF55.70
-CHF0.04(-0.07%)
At close: 4:00 PM EDT
CHF55.70
-CHF0.04(-0.07%)
Day’s Range― - ―
52-Week RangeCHF48.08 - CHF79.39
Previous CloseN/A
Volume364.76K
Average Volume (3M)370.72K
Market Cap
CHF27.67B
Enterprise ValueCHF31.95K
Total Cash (Recent Filing)CHF1.66B
Total Debt (Recent Filing)CHF5.25B
Price to Earnings (P/E)41.5
Beta1.13
Next Earnings
Aug 10, 2026EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend Yield0.51%
Share Statistics
EPS (TTM)1.65
Shares Outstanding499,700,000
10 Day Avg. Volume262,948
30 Day Avg. Volume370,724
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF71.64Price Target Upside28.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)2.76
Revenue Forecast (FY)CHF8.84B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a sizable equity base provide durable financial flexibility to fund R&D, equipment placements and share returns while absorbing cyclical demand shocks. This contained financial risk supports multiyear investment in product launches and capacity without relying on heavy external financing.
Equipment & Platform MomentumRapid Unity platform adoption expands the installed base, creating sticky follow-on consumables and service revenue. Durable platform uptake enhances customer switching costs and long-term recurring revenue from procedures, supporting sustainable surgical franchise growth beyond short-term procedure cycles.
Recurring Consumer FranchisesGrowth in contact lenses, reusable adoption and artificial tears reflect diversified, repeat-purchase revenue streams. These consumer-facing franchises smooth cyclical surgical exposure, provide steady cash flow, and amplify margin resilience through scale and brand-led pricing power over time.
Bears Say
Free Cash Flow SoftnessA recent step-down in free cash flow conversion indicates earnings are not fully converting to operating cash, reducing internal funding for launches and buybacks. Persistently weaker FCF can constrain capital allocation flexibility and raises sensitivity to working-capital and margin volatility over the medium term.
Tariff-driven Margin PressureMaterial tariff exposure raises the structural cost base and compresses gross margins unless offset by pricing or sourcing changes. Even with a lower assumed tariff rate, persistent trade-policy risk can erode margin sustainability and force either margin sacrifices or higher end-pricing, limiting profitable growth.
China Weakness & Competitive IntensitySlower growth and heightened competition in China—a key long-term market—constrain global implantable penetration and cap upside from IOL innovation. Prolonged share pressure in high-growth regions can limit revenue scaling from new launches and extend the time required to recoup launch investments.
Alcon News
0A0D FAQ
What was Alcon Inc’s price range in the past 12 months?
Alcon Inc lowest share price was CHF48.08 and its highest was CHF79.39 in the past 12 months.
What is Alcon Inc’s market cap?
Alcon Inc’s market cap is CHF27.67B.
When is Alcon Inc’s upcoming earnings report date?
Alcon Inc’s upcoming earnings report date is Aug 10, 2026 which is in 5 days.
How were Alcon Inc’s earnings last quarter?
Alcon Inc released its earnings results on May 05, 2026. The company reported CHF0.662 earnings per share for the quarter, beating the consensus estimate of CHF0.636 by CHF0.026.
Is Alcon Inc overvalued?
According to Wall Street analysts Alcon Inc’s price is currently Undervalued.
Does Alcon Inc pay dividends?
Alcon Inc pays a Annually dividend of CHF0.28 which represents an annual dividend yield of 0.51%. See more information on Alcon Inc dividends here
What is Alcon Inc’s EPS estimate?
Alcon Inc’s EPS estimate is 0.61.
How many shares outstanding does Alcon Inc have?
Alcon Inc has 499,700,000 shares outstanding.
What happened to Alcon Inc’s price movement after its last earnings report?
Alcon Inc reported an EPS of CHF0.662 in its last earnings report, beating expectations of CHF0.636. Following the earnings report the stock price went down -6.224%.
Which hedge fund is a major shareholder of Alcon Inc?
Currently, no hedge funds are holding shares in GB:0A0D
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF71.64 (28.61% Upside)
CHF71.64 (28.61% Upside)
Blogger Sentiment
Bullish
GB:0A0D Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.40%
12-Months-Change
Fundamentals
Return on Equity
0.51%
Trailing 12-Months
Asset Growth
1.97%
Trailing 12-Months
Company Description
Alcon Inc
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
0A0D Company Deck
0A0D Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely constructive picture: solid top-line growth across surgical, vision care and ocular health, strong early adoption and share gains from new product launches (Unity, PanOptix Pro, Tryptyr, Total30), a meaningful equipment acceleration and a shareholder-friendly $1.5B repurchase plan. Offsetting this optimism were market headwinds (soft cataract volumes, China weakness), tariff-driven margin pressure, modest operational disruptions (Hydrus supply, Middle East shipping) and near-term margin timing (Q2 SG&A peak). Management maintained full-year guidance (5%–7% sales growth; 70–170 bps core operating margin expansion) and positioned the back half of 2026 for stronger contribution from new products, implying overall confidence in durable growth despite short-term noise.View all GB:0A0D earnings summaries0A0D Stock 12 Month Forecast
Average Price Target
CHF71.64
▲(28.61% Upside)